CN2798942Y - Aspirin dipyridamole slow-release tablet - Google Patents
Aspirin dipyridamole slow-release tablet Download PDFInfo
- Publication number
- CN2798942Y CN2798942Y CN 200520072685 CN200520072685U CN2798942Y CN 2798942 Y CN2798942 Y CN 2798942Y CN 200520072685 CN200520072685 CN 200520072685 CN 200520072685 U CN200520072685 U CN 200520072685U CN 2798942 Y CN2798942 Y CN 2798942Y
- Authority
- CN
- China
- Prior art keywords
- layer
- aspirin
- dipyridamole
- slow
- utility
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
An aspirin dipyridamole slow-release tablet belongs to the technical field of a medicine dosage structure. The utility model aims to solve the technical problem of providing an aspirin dipyridamole slow-release tablet which has the advantages of novel dosage structure, easy quality control, easy fabrication and no requirement of special equipment. The utility model is characterized in that a tablet core of a tablet is sequentially composed of a dipyridamole layer (1), an isolating layer (2) and an aspirin layer (3). The utility model has the technical effects that the isolating layer which uses medicinal auxiliary material which does not contain the two main drugs of the aspirin layer and the dipyridamole layer is arranged between the aspirin layer and the dipyridamole layer, so the influence between the two main drugs of the aspirin layer and the dipyridamole layer is effectively isolated, and products achieve quality standards; besides, the utility model is simple in technology operation and the existing markets in market can be utilized to achieve the purpose of scale production. The slow-release tablet is suitable for patients who suffer from transient local cerebral ischemia and full ischemia, and can reduce apoplexy risk.
Description
Technical field: this utility model relates to a kind of pharmaceutical formulation structure, particularly a kind of aspirin-dipyridomole slow releasing tablet.
Background technology: aspirin, chemistry 2-(acetoxyl group) benzoic acid by name easily decomposes under alkalescence or weak basic condition and lost efficacy.Still all there is the control of limiting the quantity of to its catabolite free salicylic acid in state to aspirin and preparation thereof.Behind aspirin and the dipyridamole mixed pressuring plate, because the chemical instability of aspirin itself, between the storage life of tablet, can quicken aspirin because of the influence of dipyridamole and decompose the generation free salicylic acid, be difficult to reach quality control standard to free water poplar acid content in the aspirin.
By aspirin and dipyridamole compound preparation that German Boehringer-Ingelheim company develops, commodity are called Aggrenox
TM, go on the market by the FDA approval in March, 1999.Aggrenox
TMBe the capsule that is used for oral administration, form by the sugar coated tablet of aspirin and the slow-release micro-pill of dipyridamole in the capsule.This complex process, and need corresponding special equipment.
Summary of the invention: technical problem to be solved in the utility model is: provide a kind of new dosage form structure, quality to be easy to control, and make easy aspirin-dipyridomole slow releasing tablet.Its technical scheme is: a kind of aspirin-dipyridomole slow releasing tablet, comprise label and gastric solubleness film-coat, and it is characterized in that: described label is made of dipyridamole layer, sealing coat and aspirin layer successively.Its technique effect is: owing between aspirin layer and dipyridamole layer, do sealing coat with the pharmaceutic adjuvant that does not contain above-mentioned two kinds of principal agents, thus intercept the influence between two principal agents effectively, make product reach its quality standard; And its technological operation is simple, utilizes the existing equipment in market, can reach the purpose of large-scale production.
Description of drawings:
Fig. 1 is this utility model structural representation.
The specific embodiment:
As shown in Figure 1, the aspirin-dipyridomole slow releasing tablet, its label is made of dipyridamole layer 1, sealing coat 2 and aspirin layer 3 successively.Dipyridamole layer (being slow release layer) is made up of pharmaceutic adjuvants such as dipyridamole, microcrystalline Cellulose, hydroxypropyl emthylcellulose, Glyceryl Behenate, alcoholic solution.Sealing coat is made up of pharmaceutic adjuvants such as starch, microcrystalline Cellulose.Aspirin layer (being release layer) is made up of pharmaceutic adjuvants such as aspirin, starch, microcrystalline Cellulose, tartaric acid, Pulvis Talci.
During making:
(1) after dipyridamole, microcrystalline Cellulose and the hydroxypropyl emthylcellulose mixing with recipe quantity, the mixing that sieves, the system wet granular, 50-60 ℃ of oven dry, granulate adds Glyceryl Behenate, mixing, and back and all the other granule mixings sieve.
(2) adjuvant in intermediate layer is put 80-100 ℃ of drying after, mix homogeneously.
(3) with the microcrystalline Cellulose of release layer and starch after 80-100 ℃ of drying, and sieve after aspirin and tartaric acid mix, mix the back as immediate release section.
(4) again with slow-released part, sealing coat part with immediate release section with shallow arc towards being pressed into the three-layer tablet chip successively.
(5) chip outsourcing gastric solubleness film-coat promptly gets this medicine.
This aspirin-dipyridomole slow releasing tablet is applicable to the patient by thrombotic transience local cerebral ischemia and complete ischemia, can reduce the danger of apoplexy.Contain aspirin 25mg in the tablet, dipyridamole 200mg.Wherein, aspirin is with the stripping of rapid release mode, and dipyridamole is a slow release.
Claims (4)
1, a kind of aspirin-dipyridomole slow releasing tablet comprises label and gastric solubleness film-coat, it is characterized in that: described label is made of dipyridamole layer (1), sealing coat (2) and aspirin layer (3) successively.
2, according to claims 1 described a kind of aspirin-dipyridomole slow releasing tablet, it is characterized in that: described dipyridamole layer is made up of dipyridamole raw material and pharmaceutic adjuvant.
3, according to claims 1 described a kind of aspirin-dipyridomole slow releasing tablet, it is characterized in that: described sealing coat is made up of pharmaceutic adjuvant.
4, according to claims 1 described a kind of aspirin-dipyridomole slow releasing tablet, it is characterized in that: described aspirin layer is made up of aspirin raw material and pharmaceutic adjuvant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200520072685 CN2798942Y (en) | 2005-06-14 | 2005-06-14 | Aspirin dipyridamole slow-release tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200520072685 CN2798942Y (en) | 2005-06-14 | 2005-06-14 | Aspirin dipyridamole slow-release tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN2798942Y true CN2798942Y (en) | 2006-07-26 |
Family
ID=36841440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200520072685 Expired - Fee Related CN2798942Y (en) | 2005-06-14 | 2005-06-14 | Aspirin dipyridamole slow-release tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN2798942Y (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058558A (en) * | 2010-12-14 | 2011-05-18 | 张瑞琛 | Method for preparing aspirin dipyridamole double-layer tablets |
| CN102210693A (en) * | 2010-04-10 | 2011-10-12 | 山东新华制药股份有限公司 | Method for preparing aspirin and dipyridamole multilayer tablets |
| CN103893193A (en) * | 2012-12-26 | 2014-07-02 | 北京亚宝生物药业有限公司 | Cardiovascular disease treatment sustained-release tablets and preparation method thereof |
| CN114010632A (en) * | 2021-12-13 | 2022-02-08 | 上海汉维生物医药科技有限公司 | Enalapril maleate and furosemide compound tablet and preparation method and application thereof |
-
2005
- 2005-06-14 CN CN 200520072685 patent/CN2798942Y/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102210693A (en) * | 2010-04-10 | 2011-10-12 | 山东新华制药股份有限公司 | Method for preparing aspirin and dipyridamole multilayer tablets |
| CN102210693B (en) * | 2010-04-10 | 2013-10-09 | 山东新华制药股份有限公司 | Method for preparing aspirin and dipyridamole multilayer tablets |
| CN102058558A (en) * | 2010-12-14 | 2011-05-18 | 张瑞琛 | Method for preparing aspirin dipyridamole double-layer tablets |
| CN103893193A (en) * | 2012-12-26 | 2014-07-02 | 北京亚宝生物药业有限公司 | Cardiovascular disease treatment sustained-release tablets and preparation method thereof |
| CN103893193B (en) * | 2012-12-26 | 2016-09-14 | 北京亚宝生物药业有限公司 | A kind of slow releasing tablet treating cardiovascular disease and preparation method thereof |
| CN114010632A (en) * | 2021-12-13 | 2022-02-08 | 上海汉维生物医药科技有限公司 | Enalapril maleate and furosemide compound tablet and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102058554B (en) | Method for preparing sustained-release tablets through granulating by adopting bonding agents in atomizing states | |
| CN102357088A (en) | Metformin hydrochloride enteric-coated tablet | |
| CN2798942Y (en) | Aspirin dipyridamole slow-release tablet | |
| CN102940611A (en) | Esomeprazole magnesium contained enteric-coated tablet and preparation method thereof | |
| CN102885795A (en) | Trimetazidine dihydrochloride sustained-release tablet and preparation method thereof | |
| CN102188429A (en) | Medicinal composition for treating diabetes | |
| CN102973528A (en) | Calcitriol solid lipidic dispersion and preparation method thereof | |
| CN106265581B (en) | Tranexamic acid tablet and preparation method thereof | |
| CN103610658B (en) | Immunomodulator slow-release preparation and preparation method thereof | |
| CN102018704B (en) | Compound preparation used for treating chronic kidney diseases and preparation method thereof | |
| CN101984970A (en) | Dihydroartemisinin piperaquine phosphate tablets and preparation process thereof | |
| CN103565774A (en) | Glipizide controlled release composition as well as preparation method thereof | |
| CN102349881A (en) | Levocarnitine thin film coated tablets and preparation method thereof | |
| CN102988372B (en) | Screening and composition of main auxiliary materials of compound aspirin tablet, and preparation method of compound aspirin sheet | |
| CN107569504B (en) | Ambroxol hydrochloride dispersible tablet and preparation method thereof | |
| CN101428030A (en) | Compound dipyridamole/acetophen sustained-release capsule and preparation thereof | |
| CN103860508A (en) | Metformin hydrochloride sustained release tablet and preparation method thereof | |
| CN104173310A (en) | Stable amoxicillin tablet composition, as well as preparation method and application thereof | |
| CN108309948A (en) | Cetirizine hydrochloride Tablets and preparation method thereof | |
| CN102600141B (en) | Dispersible tablet containing amoxicillin and potassium clavulanate | |
| CN101711753A (en) | Preparation method of lansoprazole solid preparation | |
| CN103142533B (en) | Enteric coated tablet of etoposide | |
| CN106038523B (en) | A kind of potassium citrate sodium citrate piece and preparation method thereof | |
| CN102670531B (en) | A kind of Loxoprofen sodium composition | |
| CN102000338B (en) | Silicon dioxide pellet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060726 Termination date: 20130614 |